COCRYSTAL PHARMA, INC. (WA)
Registration and award facts
SAM.gov registration as of
- Net obligations since FY2025
- $498.2K
- $498,199under this UEI
- FY2026 obligations
- $0†
- Provisional
- Awards and orders
- 1
- with positive net obligations
- Latest action
- Sep 29, 2025
- SAM.gov registration
- Active
- Registration expiration date Dec 11, 2026
Registration
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Business start date
- Jan 4, 2014 (12 years)
- Location
- Bothell, WA
- State of incorporation
- Delaware
- Website
- cocrystalpharma.com
† FY2026 obligations (provisional; DoD awards signed after Jul 27, 2026 are not yet public).
Source: SAM.gov entity registration and FPDS contract actions recorded under UEI UY8UDESGRJ17. GovChime does not check exclusions.
Performance
Net obligations recorded under this UEI since FY2025. Top lists show the largest five by share of this vendor's net obligations; the shares do not sum to 100%.
Net obligations by fiscal year of action
- FY2025: $498,199
Total across 1 fiscal year: $498,199
Top awarding agencies
- Department of Health and Human Services$498,199, 100%
Top awarding sub-agencies
- National Institutes of Health$498,199, 100%
Top NAICS by obligations
Top product and service codes by obligations
- AN12Health r&d services; health care services; applied research$498,199, 100%
Capabilities
NAICS codes
- 541714Research and Development in Biotechnology (except Nanobiotechnology)(primary)Small
- 541715E
Small: small business for that NAICS, self-certified in SAM.gov registration.
SBA certifications
No certification in the SBA profile data.
Federal Capability Statement
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and clinical advancement of innovative antiviral therapeutics for serious and chronic viral diseases. The company employs a proprietary structure-based drug discovery platform supported by Nobel Prize–winning scientific expertise to design first- and best-in-class small-molecule antivirals that target highly conserved viral replication enzymes. This approach enables efficient identification, optimization, and development of broad-spectrum antiviral drug candidates. Cocrystal Pharma’s pipeline includes clinical and preclinical programs addressing influenza, norovirus, coronaviruses including SARS-CoV-2, hepatitis C, and other high-priority viral pathogens. The company has successfully advanced multiple programs through Phase 1 and Phase 2 clinical trials and collaborates with government agencies and global pharmaceutical partners to address critical public health needs.
Contracts
Latest awards and orders
- 75N93025C00038Definitive contractDepartment of Health and Human ServicesNational Institutes of HealthLatest action
Contact Info
As of . Source: SAM.gov Points of Contact.
SAM.gov registration for COCRYSTAL PHARMA, INC. lists a physical address and a separate mailing address, along with 4 verified points of contact. Past Performance contacts are the recommended outreach channel for due-diligence references; Government Business contacts handle procurement-facing correspondence.
Source: SAM.gov entity registration. Contacts displaying numeric or placeholder names have been filtered (defense-in-depth).
Physical Address
19805 N CREEK PKWY STE 100
BOTHELL, WA, 98011
USA
Mailing Address
19805 NORTH CREEK PARKWAY, SUITE 100
BOTHELL, WA, 98011
USA
Government Business Contact
SAM LEE
PRESIDENT AND CO-CEO
19805 NORTH CREEK PARKWAY SUITE 100
BOTHELL, WA, 98011
USA
Electronic Business Contact
MARIE CROUCH
DIRECTOR, PROGRAMS AND PM
19805 NORTH CREEK PARKWAY SUITE 100
BOTHELL, WA, 98011
USA
Government Business Alternate Contact
SAM LEE
PRESIDENT AND CO-CEO
19805 NORTH CREEK PARKWAY SUITE 100
BOTHELL, WA, 98011
USA
Electronic Business Alternate Contact
MARIE CROUCH
DIRECTOR, PROGRAMS AND PM
19805 NORTH CREEK PARKWAY SUITE 100
BOTHELL, WA, 98011
USA
Additional Details
As of . Source: SAM.gov Entity Registration.
COCRYSTAL PHARMA, INC. has no active federal suspension or debarment on record in SAM.gov. Current SAM.gov registration expires December 11, 2026.
Source: SAM.gov entity registration (FAR responses, registration status). Always verify active exclusions against the authoritative record on SAM.gov before contract award.
Compliance & Risk Assessment
Source: SAM.gov FAR responsesSuspension/Debarment Status
SAM.gov registration reports no active exclusion
Public Display
Entity information is publicly displayed
Disaster Relief Registry
Not registered for disaster relief
Bonding Information
No bonding information provided
EDI
Not declared in SAM.gov
Business Structure
Source: SAM.govRegistration Details
Source: SAM.govInitial Registration
Last Update
Registration Activation
Fiscal Year End
Country of Incorporation
Congressional District
Other contractors in Washington with primary NAICS 541714
- Primary Bioscience, Inc.Seattle, WA
- A-Alpha Bio IncSeattle, WA
- Adaptive Biotechnologies CorporationSeattle, WA
- Parse Biosciences, Inc.Seattle, WA
- Modus Health LLCMountlake Terrace, WA
- JW3 Biotechnologies LLCBothell, WA